Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials, BMJ Open

Review (16 RCTs;n=8152) found hydroxychloroquine(HQ) probably& lopinavir/ritonavir may increase risk of diarrhoea& nausea&/or vomiting. HQ probably increases cardiotoxicity risk& cognitive dysfunction/delirium(CD/D). Remdesivir may have no important effect on AKI risk or CD/D.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news